PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS
PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS IRVINE, CA, October 29, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2027 fi
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on sales growth and profit decline, enabling traders to reassess valuation.
Market read
First‑report earnings for a micro‑cap medical device firm; modest trading relevance.
What to watch
The contribution from newly acquired APM subsidiary and upcoming validation unit shipments may boost future margins.
PRO-DEX, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS
Net sales, gross profit, gross margin and operating income increased from the year-ago quarter, but GAAP net income and diluted EPS declined because unrealized gains on investments were materially lower than in the prior-year period.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $20.56M | – | 11% |
| Cost of sales, three months ended September 30, 2026GAAP | 13,703 | – | – |
| Gross profit, three months ended September 30, 2026GAAP | 6,857 | – | 28% |
| Gross margin, three months ended September 30, 2026GAAP | 33% | – | increased by 4 percentage points |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | 2,132 | – | – |
| Research and development costs, three months ended September 30, 2026GAAP | 1,210 | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | 3,342 | – | 48% |
| Operating income, three months ended September 30, 2026GAAP | 3,515 | – | 13% |
| Interest and dividend income, three months ended September 30, 2026GAAP | 51 | – | – |
| Unrealized gain on investments, three months ended September 30, 2026GAAP | 73 | – | – |
| Interest expense, three months ended September 30, 2026GAAP | (260) | – | – |
| Total other income (expense), three months ended September 30, 2026GAAP | (136) | – | – |
| Income before income taxes, three months ended September 30, 2026GAAP | 3,379 | – | – |
| Provision for income taxes, three months ended September 30, 2026GAAP | 331 | – | – |
| Net income, three months ended September 30, 2026GAAP | $3.05M | – | – |
| Basic net income per share, three months ended September 30, 2026GAAP | $ 0.95 | – | – |
| Diluted net income per share, three months ended September 30, 2026GAAP | $ 0.92 | – | – |
| Weighted-average common shares outstanding, basic, three months ended September 30, 2026GAAP | 3,206,304 | – | – |
| Weighted-average common shares outstanding, diluted, three months ended September 30, 2026GAAP | 3,315,415 | – | – |
| Common shares outstanding, September 30, 2026GAAP | 3,203,334 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
What drove it
- Net sales increased $2.1 million, or 11%, driven primarily by a $3.3 million increase in medical device revenue, inclusive of rebates.
- The $3.3 million increase in medical device revenue included $1.8 million related to the next-generation handpiece sold to the Company's largest customer.
- APM generated an increase in revenue of $511,000, exclusive of inter-company sales in the amount of $814,000 which are eliminated in consolidation.
- Gross margin increased by 4 percentage points to 33% due primarily to favorable product mix.
- Operating expenses increased because of a $442,000 increase in engineering and a $642,000 increase in selling, general and administrative expenses.
Concerns
- Repairs of the legacy handpiece sold to the Company's largest customer decreased $1.7 million.
- Selling, general and administrative expense included $466,000 from APM's separate operations and $195,000 of higher personnel costs related to accounting, mergers and acquisitions, human resources, and information technology.
- Net income included unrealized gains on marketable equity investments of $73,000, compared with unrealized gains of $3.3 million in the year-ago quarter.
- The Company stated that its investments are recorded at estimated fair value and that period-to-period valuation can be highly volatile.
- Interest expense was (260), compared with (200) in the year-ago quarter.
What to watch
- Expected shipment of validation units to the Monogram and Zimmer Biomet teams later this fiscal year.
- Revenue from the next-generation handpiece sold to the Company's largest customer.
- The level of repairs of the legacy handpiece sold to that customer.
- APM revenue contribution and the operating-expense impact of APM's separate operations.
- Future unrealized gains or losses on marketable equity investments.
Balance sheet and cash flow
- Cash and cash equivalents: $ 11,759 at September 30, 2026, compared to $ 8,192 at June 30, 2026.
- Investments: 1,230 at September 30, 2026, compared to 1,150 at June 30, 2026.
- Accounts receivable, net: 17,507 at September 30, 2026, compared to 21,205 at June 30, 2026.
- Inventory: 21,899 at September 30, 2026, compared to 21,458 at June 30, 2026.
- Notes payable: 4,171 at September 30, 2026, compared to 4,205 at June 30, 2026.
- Notes payable, net of current portion: 12,270 at September 30, 2026, compared to 13,266 at June 30, 2026.
- Total assets: $ 76,589 at September 30, 2026, compared to $ 74,509 at June 30, 2026.
- Total liabilities: 27,243 at September 30, 2026, compared to 26,876 at June 30, 2026.
- Total shareholders’ equity: 49,346 at September 30, 2026, compared to 47,633 at June 30, 2026.
Analysis
Pro-Dex reported a higher-revenue fiscal 2027 first quarter. Net sales were $ 20,560 versus $ 18,530 in the year-ago quarter, with the release attributing the increase primarily to a $3.3 million increase in medical device revenue, inclusive of rebates. That growth included $1.8 million from the next-generation handpiece sold to the Company's largest customer and $511,000 of APM revenue, excluding $814,000 of inter-company sales eliminated in consolidation. These contributions were partly offset by a $1.7 million decline in repairs of the legacy handpiece sold to that customer.
Profitability in the core operations improved. Gross profit was 6,857 versus 5,367, while gross margin increased by 4 percentage points to 33% from 29%, primarily because of favorable product mix. Operating income increased to 3,515 from 3,109. The improvement in gross profit was partly offset by total operating expenses of 3,342, up from 2,258, including increased engineering costs and higher selling, general and administrative expenses.
GAAP bottom-line results declined despite the improvement in operating income. Net income was $ 3,048, or $ 0.92 per diluted share, compared with $ 4,680, or $ 1.40 per diluted share. The release identifies unrealized gains on marketable equity investments of 73 in the current quarter versus 3,299 in the year-ago period as the principal reason for the lower net income. Management also stated that investment valuations can be highly volatile because investments are recorded at estimated fair value.
The balance sheet showed cash and cash equivalents of $ 11,759 at September 30, 2026, compared with $ 8,192 at June 30, 2026. Inventory was 21,899 compared with 21,458, while accounts receivable declined to 17,507 from 21,205. Notes payable was 4,171 and notes payable, net of current portion, was 12,270. The release provided no quantified financial outlook, although management expects to ship validation units to the Monogram and Zimmer Biomet teams later in the fiscal year.
Management, verbatim
We are pleased with our first quarter results and continued top line revenue growth.
Richard L. (“Rick”) Van Kirk, President and Chief Executive Officer
We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.
Richard L. (“Rick”) Van Kirk, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quantified forward financial guidance for revenue, gross margin, operating expenses, tax rate, earnings, or cash flow was not provided.
- Prior-release outlook was not provided.
- Operating cash flow was not provided.
- Free cash flow was not provided.
- Share repurchases and dividends were not provided.
- Formal reportable segment revenue was not provided.
- Non-GAAP financial measures were not provided.
- Effective tax rate was not provided.
- Sequential comparisons for income-statement metrics were not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Pro‑Dex, Inc. (NasdaqCM:PDEX) filed its 8‑K reporting Q1 FY2027 results, the first public disclosure of these numbers.
Ticker impact
Q1 FY2027 results show 11% revenue growth but net income fell 36% YoY, indicating mixed performance.
likely modest downside as investors price in lower earnings
Revenue rose, but net income dropped sharply and guidance was not provided, which typically weighs on price.
Market effects
Shows continued demand for orthopedic devices, but profit pressure may affect peer valuations.
Limited to US small‑cap medical device niche.
Low; no broader macro impact.
Counterpoint
Revenue acceleration could signal a turnaround if cost controls improve, offering upside potential.
Key entities
- companyPro‑Dex, Inc.
Medical device manufacturer reporting Q1 FY2027 results.
- subsidiaryAdvanced Precision Machining, LLC
Newly acquired unit contributing $511k revenue.